BWA
SPRO icon

BDO Wealth Advisors’s Spero Therapeutics SPRO Stock Holding History

BDO Wealth Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-75
Closed -$1K – 1121
2021
Q2 		$1K Buy
+75
New +$1.05K ﹤0.01% 1074

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BDO Wealth Advisors's SPRO Position: Q3 2021 in Review

BDO Wealth Advisors sold out of Spero Therapeutics (SPRO) in Q3 2021, closing a stake of 75 shares — an estimated $1K sold.

BDO Wealth Advisors first reported a position in SPRO in Q2 2021 and held it in 1 quarter. The position peaked at $1K in Q2 2021. 87 funds tracked by Wall St. Rank hold SPRO as of Q3 2021.

  • BDO Wealth Advisors reported no remaining Spero Therapeutics position as of Q3 2021 after selling out during the quarter.
  • BDO Wealth Advisors sold 75 Spero Therapeutics shares in Q3 2021, an estimated $1K.
  • BDO Wealth Advisors first reported a position in Spero Therapeutics in Q2 2021 and held it in 1 quarter.
  • BDO Wealth Advisors's Spero Therapeutics position peaked at $1K in Q2 2021.
  • 87 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2021.

Based on BDO Wealth Advisors's 13F filing for Q3 2021, filed 9 Nov 2021.